Summit Creek Advisors buys $22,212,059 stake in BIO-TECHNE Corp (TECH)

BIO-TECHNE Corp (TECH) : Summit Creek Advisors scooped up 16,081 additional shares in BIO-TECHNE Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 234,255 shares of BIO-TECHNE Corp which is valued at $22,212,059.BIO-TECHNE Corp makes up approximately 3.43% of Summit Creek Advisors’s portfolio.

BIO-TECHNE Corp opened for trading at $93.82 and hit $95.04 on the upside on Friday, eventually ending the session at $94.82, with a gain of 0.96% or 0.9 points. The heightened volatility saw the trading volume jump to 2,11,348 shares. Company has a market cap of $3,526 M.

Other Hedge Funds, Including , Cwm reduced its stake in TECH by selling 82 shares or 71.93% in the most recent quarter. The Hedge Fund company now holds 32 shares of TECH which is valued at $3,034. Acadian Asset Management sold out all of its stake in TECH during the most recent quarter. The investment firm sold 1,407 shares of TECH which is valued $130,753.State Of Alaska Department Of Revenue boosted its stake in TECH in the latest quarter, The investment management firm added 1,790 additional shares and now holds a total of 2,683 shares of BIO-TECHNE Corp which is valued at $249,331. BIO-TECHNE Corp makes up approx 0.03% of State Of Alaska Department Of Revenue’s portfolio.Capstone Asset Management Co boosted its stake in TECH in the latest quarter, The investment management firm added 430 additional shares and now holds a total of 6,300 shares of BIO-TECHNE Corp which is valued at $585,459. BIO-TECHNE Corp makes up approx 0.02% of Capstone Asset Management Co’s portfolio.

On the company’s financial health, BIO-TECHNE Corp reported $0.88 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.82. The company had revenue of $120.90 million for the quarter, compared to analysts expectations of $118.43 million. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.82 EPS.

Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.

Leave a Reply

BIO-TECHNE Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on BIO-TECHNE Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.